Abstract |
An effective therapy for chronic myocardial infarction (MI) has yet to be developed. Vascular endothelial growth factor ( VEGF) promotes angiogenesis and improves cardiac function after MI. However, non-targeted delivery of VEGF decreases its therapeutic efficacy. In this study, for targeting the cardiac extracellular matrix, a collagen-binding domain (CBD) VEGF was used to bind specifically to the collagen-rich cardiac extracellular matrix. When intramyocardially injected into the peri- infarct region of a chronically infarcted porcine heart, CBD- VEGF attenuated the remodeling of the left ventricle with a decreased infarct size and promoted cardiomyocyte survival and angiogenesis 3 months after injection. In the 12-month trial, mature vessel networks and myocardium-like tissues were observed in the infarct region after CBD- VEGF injection. Also these beneficial effects might derive from CBD- VEGF significantly protecting cardiomyocytes from apoptosis and recruiting cardiac progenitor cells to the infarcted region. These results demonstrated that CBD- VEGF could be a promising therapeutic strategy for chronic MI.
|
Authors | Chunying Shi , Yannan Zhao , Yun Yang , Cheng Chen , Xianglin Hou , Jun Shao , Hao Yao , Qingguo Li , Yujun Xia , Jianwu Dai |
Journal | Biomaterials science
(Biomater Sci)
Vol. 6
Issue 2
Pg. 356-363
(Jan 30 2018)
ISSN: 2047-4849 [Electronic] England |
PMID | 29266144
(Publication Type: Journal Article)
|
Chemical References |
- Peptide Fragments
- Vascular Endothelial Growth Factor A
- Collagen
|
Topics |
- Animals
- Apoptosis
- Binding Sites
- Collagen
(metabolism)
- Extracellular Matrix
(metabolism)
- Heart Ventricles
(drug effects, pathology)
- Injections, Intralesional
- Male
- Myocardial Infarction
(drug therapy)
- Myocytes, Cardiac
(drug effects, metabolism)
- Neovascularization, Physiologic
- Peptide Fragments
(administration & dosage, pharmacology, therapeutic use)
- Protein Binding
- Swine
- Vascular Endothelial Growth Factor A
(chemistry)
|